Acarix announced the release of a new study published in the March 2023 issue of the scientific journal Heart. The study confirms that the CADScor®?System has a very high rule-out accuracy in low-risk patients with chest pains, and potential to reduce the need for further, unnecessary clinical testing in this patient group by almost 50%. The clinical study, published in Heart by Rasmussen et al, investigated the diagnostic performance of the Acarix CADScor System on 1,683 patients seeking healthcare for stable chest pain symptoms, and that were referred on for coronary CT angiography.

The study also evaluated the potential of the CADScor System to reduce the proportion of low-risk patients undergoing unnecessary cardiac assessments based on ESC-PTP guidelines alone. The study concluded that the CADScor System had a very high rule-out accurate of coronary artery disease (CAD) in the patient cohort. Furthermore, the study showed that nearly half of all grey zone patients (with low-probability of CAD with ESC-PTP 5% to =15%) could be reclassified to be assessed with the CADScor System, showing a clear potential to help avoid further unnecessary clinical testing in larger patient groups.